Array Technologies, Inc. Reports Financial Results for the Second Quarter 2022 – Outperforms on revenue and adjusted EBITDA, delivers organic growth of 79% in Array Legacy Operation segment, and has
Go back to Array Technologies, Inc. Reports Financial Results for the Second Quarter 2022 – Outperforms on revenue and adjusted EBITDA, delivers organic growth of 79% in Array Legacy Operation segment, and has| Array Biopharma, Inc. (NASDAQ: ARRY) | Delayed: 4.06 -0.18 (4.25%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.24 | 52 Week High | $7.27 | |||
| Open | $4.07 | 52 Week Low | $2.39 | |||
| Day High | $4.15 | P/E | N/A | |||
| Day Low | $3.89 | EPS | $-0.61 | |||
| Volume | 17,301,105 | |||||
